I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II

SHANGHAI and GAITHERSBURG,Md.,June 12,2020 --I-Mab (the "Company") (Nasdaq: IMAB),a clinical stage biopharmaceutical company committed to the discovery,development and commercialization of novel biologics,will be presenting preclinical data on a newly developed,novel asset TJ-CD4B,at the American Association for Cancer Research (AACR) Virtual Annual Meeting IIon June 22-24,2020.

TJ-CD4B,also known as ABL111,is a Claudin 18.2 and 4-1BB bispecific antibody jointly developed with South Korea-based ABL Bio,Inc. (Kosdaq: 298380,hereafter "ABL"). TJ-CD4B is from I-Mab's emerging bispecific antibody portfolio designed to create novel drug molecules that synergize two pathways for better clinical efficacy. By linking with an antibody against Claudin 18.2,a gastric- and pancreatic-specific cancer antigen,TJ-CD4B/ABL111 is uniquely structured to supercharge T cells in a Claudin 18.2-dependent manner,enhancing anti-tumor immunity while potentially minimizing toxicity.

The pre-clinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-Mab's bispecific antibody portfolio,reflecting Company's discovery and CMC capabilities to engineer novel molecules with combined target specificities. I-Mab plans to advance more novel bispecific antibodies towards clinical development stage,following the lead of TJ-CD4B/ABL111.

The poster presentation (Abstract #5644) is available for on-demand viewing starting 9:00 am EDT,22 June,and will remain for viewing by registered attendees for at least three months after the virtual meeting.

The abstract is available online at:

https://www.abstractsonline.com/pp8/#!/9045/sessions/5644/1

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic,global biotech company exclusively focused on developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases. Company's mission is to bring transformational medicines to patients through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms,proven preclinical and clinical development expertise,and world-class GMP manufacturing capabilities. I-Mab has offices in China and the United States. For more information,please visit http://ir.i-mabbiopharma.com/.

Forward Looking Statements

This press release includes certain disclosures which contain "forward-looking statements." You can identify forward-looking statements because they contain words such as "anticipate" and "expected." Forward-looking statements are based on I-Mab's current expectations and assumptions. Because forward-looking statements relate to the future,they are subject to inherent uncertainties,risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements,which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements,whether as a result of new information,future events or otherwise,except as may be required by law.

For more information,please contact:

I-Mab

Jielun Zhu,CFO

E-mail: jielun.zhu@i-mabbiopharma.com

Office line: +86 21 6057 8000

Gigi Feng,Vice President and Global Head of Corporate Communications

E-mail: Gigi.Feng@i-mabbiopharma.com

Office line: +86 21 6057 8000

Investor Inquiries:

Burns McClellan,Inc. (Americas and Europe)

Steve Klass

E-mail: sklass@burnsmc.com

Office line: +1 212 213 0006

The Piacente Group,Inc. (Asia)

Emilie Wu

E-mail: emilie@thepiacentegroup.com

Office line: + 86 21 6039 8363

View original content to download multimedia:/news-releases/i-mab-and-abl-bio-to-present-preclinical-data-for-joint-bispecific-antibody-program-at-the-2020-american-association-for-cancer-research-virtual-meeting-ii-301075057.html